Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain

References

• Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine 2006;31:2724–7.
   PubMed Web of Science ®Google Scholar
• Asche CV, Kirkness CS, McAdam-Marx C, Fritz JM. The societal costs of low back pain: data published between 2001 and 2007. J Pain Palliat Care Pharmacother 2007;21:25–33.
   PubMedGoogle Scholar
• Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008;8:8–20.
   PubMed Web of Science ®Google Scholar
• Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff 2002;21:105–11.
   PubMed Web of Science ®Google Scholar
• Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ. Outcome of low back pain in general practice: a prospective study. BMJ 1998;316:1356–9.
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778–99.
   PubMed Web of Science ®Google Scholar
• Airaksinen O, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;15:S192–300.
   PubMed Web of Science ®Google Scholar
• Ekman M, Jonhagen S, Hunsche E, Jonsson L. Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. Spine 2005;30:1777–85.
   PubMed Web of Science ®Google Scholar
• Kosinski MR, Schein JR, Vallow SM, et al. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. Curr Med Res Opin 2005;21:849–62.
   PubMed Web of Science ®Google Scholar
• Salaffi F, De Angelis R, Stancati A, Grassi W. Health-related quality of life in multiple musculoskeletal conditions: a cross-sectional population based epidemiological study. II. The MAPPING study. Clin Exp Rheumatol 2005;23:829–39.
   PubMed Web of Science ®Google Scholar
• Yarlas A, Miller K, Wen W, et al. A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naive patients with moderate-to-severe chronic low back pain. J Pain 2013;14:14–23.
   PubMed Web of Science ®Google Scholar
• Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol/Acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther 2003;25:1123–41.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282–90.
   PubMed Web of Science ®Google Scholar
• Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med 2010;11:1477–88.
   PubMed Web of Science ®Google Scholar
• Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 2010;32:844–60.
   PubMed Web of Science ®Google Scholar
• Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain 2011;12:1163–73.
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2011;42:903–17.
   PubMed Web of Science ®Google Scholar
• Miller K, Yarlas A, Wen W, et al. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother 2013;14:269–77.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–38.
   PubMedGoogle Scholar
• Chapman JR, Norvell DC, Hermsmeyer JT, et al. Evaluating common outcomes for measuring treatment success for chronic low back pain. Spine 2011;36:S54–68.
   PubMed Web of Science ®Google Scholar
• Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309–18.
   PubMed Web of Science ®Google Scholar
• Marcus NJ, Shrikhande AA, McCarberg B, Gracely E. A preliminary study to determine if a muscle pain protocol can produce long-term relief in chronic back pain patients. Pain Med 2013;14:1212–21.
   PubMed Web of Science ®Google Scholar
• Whynes DK, McCahon RA, Ravenscroft A, Hodgkinson V, Evley R, Hardman JG. Responsiveness of the EQ-5D health-related quality-of-life instrument in assessing low back pain. Value Health 2013;16:124–32.
   PubMed Web of Science ®Google Scholar
• Cleeland CS. The brief pain inventory user guide. Houston: 2009. Available from:http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf.
   Google Scholar
• Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989;10:407–15.
   PubMedGoogle Scholar
• Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010;11:109–18.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Spaeth M, Clauw DJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res 2011;63:821–6.
   PubMed Web of Science ®Google Scholar
• Wong K, Zeng L, Zhang L, et al. Minimal clinically important differences in the brief pain inventory in patients with bone metastases. Support Care Cancer 2013;21:1893–9.
   PubMed Web of Science ®Google Scholar
• Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988;75:383–6.
   Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd edition. Lawrence Erlbaum Associates; Hillsdale, NJ: 1988.
   Google Scholar
• Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. BMC Musculoskelet Disord 2008;9:55.
   PubMed Web of Science ®Google Scholar
• Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine 2005;30:1331–4.
   PubMed Web of Science ®Google Scholar
• Hagg O, Fritzell P, Nordwall A. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J 2003;12:12–20.
   PubMed Web of Science ®Google Scholar